The National Pharmaceutical Pricing Authority (NPPA), on June 23, 2026, issued an Office Memorandum directing all manufacturers of scheduled formulations to ensure timely compliance with the quarterly submission requirements under Paragraph 21(1) of the Drugs (Prices Control) Order (DPCO), 2013.
NPPA reiterated that every manufacturer of scheduled formulations is required to submit Form III prescribed under Schedule II of the DPCO, 2013 on a quarterly basis for monitoring the production and availability of scheduled formulations and the Active Pharmaceutical Ingredients (APIs) contained therein. The Authority has designated the Integrated Pharmaceutical Database Management System (IPDMS 2.0) as the online platform for submission of Form III. However, it observed that several manufacturers have not been regularly filing the prescribed returns, resulting in gaps in monitoring the availability of scheduled formulations and APIs.
Accordingly, NPPA has directed all entities falling within the definition of "manufacturer" under the DPCO, 2013 to submit Form III regularly through IPDMS 2.0 and immediately file any pending returns for missed quarters. The Authority has cautioned that non-submission or delayed submission of Form III may invite action under the Drugs (Prices Control) Order, 2013 and other applicable regulations.
[Notification No. 15(108)/2021/Div. III/NPPA Part (1)]
